Last winter you might have seen the headlines about rising hospitalizations from respiratory

sensicial virus or RSV.

Health care providers now have tools to help prevent lower respiratory tract disease caused by

RSV in adults 60 years and older. This fall and winter is the first

respiratory season when RSV vaccinations will be available in the United States to help protect against

RSV for older adults. Scientific American custom media recently sat down with Dr. Temi

Fulleronmy, Vice President and Head, U.S. Medical and Clinical Affairs Vaccines at GSK in this

GSK sponsored segment. To learn more about RSV, the immune system, and vaccinations.

Well, Dr. Fullar on me, it's such a pleasure to talk with you today.

Thank you for joining me.

Thank you for having me on your podcast.

So before we dig into the details of this

conversation I'm really curious about you and your background. Specifically you've

spent your whole career combating diseases and viruses.

You've worked on meningitis, polio, HIV, both in Nigeria and in the U.S.

So what sparked this interest for you?

I trained as a physician and I also approach

got re-training in public health and public policy.

This training is important for my career because I think the intersection between clinical practice,

public care and public policy, and the broader scientific community is so important that a public health policy have strong

foundation in science and I've spent a lot of my careers helping to inform

public health policies and programs based on sound research and data.

...